Bolt Biotherapeutics Acquires Prana Therapies in Reverse Merger, Secures USD 120 Million Financing
Bolt Biotherapeutics is acquiring Prana Therapies in a reverse merger and securing USD 120 million in financing.
Related stories
Trane Technologies Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 02:19 PM UTC
Pediatrix Medical Group Reports Quarterly Results
Pediatrix Medical Group reported results for the quarter ended September 30; the supplied item provides no financial figures.
M impact | EQUITY | Oct 29, 2026, 02:19 PM UTC
Patrick Industries Shares Rise More Than 4% After Fiscal Q3 Beat
Patrick Industries shares were up over 4% on Thursday after the company reported a fiscal Q3 beat.
M impact | EQUITY | Oct 29, 2026, 02:19 PM UTC
Microsoft Reports Q1 2027 Earnings, Beats Wall Street Expectations
Microsoft beat Wall Street expectations on both its top and bottom line in its Q1 2027 earnings, according to the report. Its stock slipped amid a broad decline in technology stock
M impact | EQUITY | Oct 29, 2026, 02:18 PM UTC
ADAMA Reports Q3 Revenue of $897M and Net Loss of $115M
Q3 2026 revenue fell about 4% year over year to $897M. Adjusted EBITDA declined 22% year over year to $93M.
M impact | EQUITY | Oct 29, 2026, 02:18 PM UTC
AkzoNobel Invests USD60 Million to Expand North American Production
AkzoNobel will invest USD60 million to expand powder coatings production in North America.
M impact | EQUITY | Oct 29, 2026, 02:17 PM UTC